Background
Methods
Subject selection
Experimental protocol
Study procedures
Statistical methods
Results
Baseline characteristics
RhGH + N = 11 | RhGH - N = 11 | P | |
---|---|---|---|
Age (years) | 16.2 ± 2.6 | 16.9 ± 2.2 | 0.50 |
Bone age (years) | 16.9 ± 1.2 | 17.2 ± 1.3 | 0.56 |
Weight (kg) | 104.7 ± 24.8 | 97.4 ± 15.4 | 0.42 |
BMI (kg/m2) | 40.4 ± 8.4 | 36.6 ± 6.4 | 0.25* |
BMI SDS | 2.3 ± 0.4 | 2.1 ± 0.4 | 0.22 |
Waist circumference (cm) | 119.4 ± 17.1 | 115.0 ± 14.8 | 0.53 |
W/H ratio | 0.95 ± 0.06 | 0.93 ± 0.08 | 0.62 |
SAT (cm2) | 615.6 ± 175.0 | 580.0 ± 176.9 (N = 9) | 0.66 |
VAT (cm2) | 90.6 ± 35.3 | 87.1 ± 31.8 (N = 9) | 0.82 |
TAT (cm2) | 706.2 ± 203.5 | 667.2 ± 179.8 (N = 9) | 0.66 |
Thigh subcutaneous fat (cm2) | 224.2 ± 69.4 | 221.4 ± 96.3 | 0.95 |
Lean mass (grams) | 54353 ± 9719 | 52276 ± 6842 | 0.57 |
IGF-1 (ng/mL) | 250.6 ± 129.9 | 271.8 ± 73.1 | 0.64 |
2 HR glucose (OGTT) (mg/dL) | 107.1 ± 20.5 | 114.0 ± 18.5 | 0.42 |
HbA1c (%) | 5.78 ± 0.30 | 5.49 ± 0.30 |
0.03
|
Insulin uU/mL | 26.4 ± 21.3 | 40.1 ± 37.2 | 0.29* |
Total cholesterol (mg/dL) | 167.6 ± 38.3 | 156.0 ± 33.5 | 0.46 |
LDL (mg/dL) | 103.8 ± 28.8 | 92.6 ± 30.1 | 0.33* |
HDL (mg/dL) | 45.1 ± 9.4 | 43.3 ± 8.5 | 0.64 |
VLDL (mg/dL) | 18.6 ± 9.4 | 20.1 ± 8.0 | 0.70 |
Triglycerides (mg/dL) | 93.0 ± 47.0 | 100.6 ± 39.8 | 0.69 |
hsCRP (mg/L) | 4.47 ± 2.76 | 3.41 ± 3.29 | 0.25* |
sICAM-1 (ng/mL) | 268.7 ± 72.5 | 220.9 ± 56.4 | 0.10 |
Six-month changes in nutritional measures
Six-month changes in IGF-1 levels
RhGH + | RhGH - | ||||||
---|---|---|---|---|---|---|---|
Baseline | 6-month N = 5 | 6-month delta | Baseline | 6-month N = 7 | 6-month delta | 6 month delta P | |
Weight (kg) | 99.9 ± 29.5 | 100.6 ± 30.9 | 0.7 ± 4.3 | 96.5 ± 18.1 | 100.4 ± 23.1 | 3.9 ± 6.6 | 0.81* |
BMI (kg/m2) | 39.6 ± 10.2 | 39.8 ± 10.8 | 0.2 ± 2.0 | 36.4 ± 7.3 | 37.8 ± 9.6 | 1.4 ± 2.5 | 0.81* |
Waist circumference (cm) | 115.4 ± 21.7 | 113.7 ± 23.1 | -1.7 ± 4.0 | 112.4 ± 17.0 | 112.5 ± 21.2 | 0.1 ± 6.5 | 0.60 |
W/H ratio | 0.94 ± 0.06 | 0.95 ± 0.06 | 0.003 ± 0.03 | 0.91 ± 0.08 | 0.91 ± 0.08 | -0.005 ± 0.04 | 0.72 |
SAT (cm2) | 578.5 ± 234.8 | 577.4 ± 232.9 | -1.1 ± 60.8 | 570.0 ± 206.4 | 606.3 ± 231.1 | 36.3 ± 51.6 (N = 6) | 0.30 |
VAT (cm2) | 92.7 ± 36.6 | 93.3 ± 47.3 | 0.6 ± 29.9 | 90.4 ± 39.6 | 98.4 ± 43.5 | 8.0 ± 31.9 (N = 6) | 0.70 |
TAT (cm2) | 671.3 ± 264.1 | 670.7 ± 278.9 | -0.5 ± 83.3 | 660.3 ± 209.1 | 704.6 ± 234.5 | 44.3 ± 63.1 (N = 6) | 0.34 |
Thigh subcutaneous fat (cm2) | 217.7 ± 72.1 | 208.7 ± 73.1 | -9.0 ± 16.0 | 228.5 ± 103.4 | 211.2 ± 72.7 | 18.6 ± 29.0 (N = 6) | 0.08* |
Lean mass (grams) | 50741.3 ± 7963.2 | 50758.1 ± 8735.6 | 17 ± 2160 | 50659.5 ± 7149.8 | 51360.7 ± 7309.6 | 701 ± 2325 | 0.62 |
IGF-1 (ng/mL) | 235.4 ± 61.9 | 234.0 ± 48.5 | -1.4 ± 79.4 | 266.0 ± 83.6 | 185.9 ± 58.0 | -80.1 ± 48.8 | 0.06 |
2 HR-glucose (OGTT) (mg/dL) | 119.8 ± 14.8 | 113.2 ± 17.6 | -6.6 ± 17.0 | 112.7 ± 14.2 | 135.1 ± 23.7 | 22.4 ± 28.8 | 0.07 |
HbA1c (%) | 5.62 ± 0.30 | 5.58 ± 0.16 | -0.04 ± 0.17 | 5.47 ± 0.25 | 5.61 ± 0.30 | 0.14 ± 0.08 |
0.03
|
Insulin uU/mL | 25.4 ± 25.7 | 22.6 ± 17.8 | -2.8 ± 11.7 | 41.9 ± 41.0 | 27.1 ± 22.5 | -14.8 ± 38.3 | 0.94* |
Total cholesterol (mg/dL) | 189.2 ± 42.6 | 151.4 ± 27.8 | -37.8 ± 23.9 | 162.1 ± 39.7 | 153.6 ± 34.8 | -8.6 ± 15.5 |
0.03
|
LDL (mg/dL) | 121.2 ± 27.7 | 95.4 ± 22.4 | -25.8 ± 12.8 | 98.3 ± 35.8 | 87.6 ± 28.0 | -10.7 ± 11.9 | 0.06 |
HDL (mg/dL) | 48.2 ± 13.4 | 41.6 ± 8.2 | -6.6 ± 6.1 | 44.0 ± 7.4 | 45.0 ± 5.2 | 1.0 ± 5.1 |
0.04
|
VLDL (mg/dL) | 19.8 ± 11.2 | 14.4 ± 6.0 | -5.4 ± 9.6 | 19.9 ± 7.0 | 21.0 ± 16.3 | 1.1 ± 11.7 | 0.48* |
Triglycerides (mg/dL) | 99.4 ± 55.7 | 71.6 ± 29.5 | -27.8 ± 46.8 | 99.1 ± 35.5 | 105.3 ± 24.9 | 6.1 ± 58.4 | 0.57* |
hsCRP (mg/L) | 3.5 ± 2.1 | 2.69 ± 1.8 | -0.77 ± 2.36 | 4.4 ± 3.8 | 4.27 ± 4.6 | -0.09 ± 1.79 | 0.58 |
sICAM-1 (ng/mL) | 226.4 ± 79.3 | 204.2 ± 74.5 | -22.2 ± 30.3 | 241.1 ± 48.1 | 262.2 ± 74.8 | 21.1 ± 33.3 |
0.04
|
Six-month changes in body composition
Six-month changes in cardiovascular risk markers
Lipid levels
Markers of inflammation
Six-month changes in glycemic status
Adverse events over the 6-month study duration
Event type | Total number of adverse events | Adverse events | |
---|---|---|---|
RhGH + (N) | RhGH - (N) | ||
Serious adverse events
| - | - | - |
Non-serious adverse events
| |||
Hyperglycemia related events
| |||
IGT at 3 or 6-month (OGTT) | 6 | 2 | 4 |
Polyuria/Polydipsia | 4 | 3 | 1 |
HbA1c > 6.4% | 1 | 1 | - |
Symptoms that may relate to raised ICP
| |||
Headache | 7 | 4 | 3 |
Nausea with vomiting | 1 | 1 | - |
Nausea without vomiting | 3 | 3 | - |
Dizziness without headache | 1 | - | 1 |
Blurry vision | 1 | 1 | - |
Arthralgias/Fluid retention related events
| |||
Arthralgia | 2 | 2 | - |
Back pain | 5 | 4 | 1 |
Myalgia | 1 | 1 | - |
Edema | - | - | - |
Menstrual cycle related events
| |||
Change in menstrual Flow | 5 | 3 | 2 |
Injection related events
| |||
Bruising/Irritation at injection site | 4 | 2 | 2 |
Bruising/Irritation at blood sampling site | 1 | 1 | - |
Others
| |||
Hypertension | 1 | - | 1 |
Lightheadedness | - | - | - |
ED visit for wheezing with URI | 1 | - | 1 |
Abdominal pain | 2 | 2 | - |
Upper respiratory Infection | 1 | 1 | - |
Nasal congestion (with URI) | 1 | 1 | - |
Fatigue | 2 | - | 2 |
Eczema | 1 | - | 1 |